| Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease E Scorletti, PR Afolabi, EA Miles, DE Smith, A Almehmadi, A Alshathry, ... Gastroenterology 158 (6), 1597-1610. e7, 2020 | 198 | 2020 |
| Steatotic liver disease, MASLD and risk of chronic kidney disease J Bilson, A Mantovani, CD Byrne, G Targher Diabetes & metabolism 50 (1), 101506, 2024 | 34 | 2024 |
| Non-alcoholic fatty liver disease: a multi-system disease influenced by ageing and sex, and affected by adipose tissue and intestinal function J Bilson, JK Sethi, CD Byrne Proceedings of the Nutrition Society 81 (2), 146-161, 2022 | 32 | 2022 |
| Growth differentiation factor-15 and the association between type 2 diabetes and liver fibrosis in NAFLD J Bilson, E Scorletti, LB Bindels, PR Afolabi, G Targher, PC Calder, ... Nutrition & diabetes 11 (1), 32, 2021 | 23 | 2021 |
| Heterogeneity of white adipocytes in metabolic disease J Bilson, JK Sethi, CD Byrne Current Opinion in Clinical Nutrition & Metabolic Care 26 (2), 72-77, 2023 | 8 | 2023 |
| Markers of adipose tissue fibrogenesis associate with clinically significant liver fibrosis and are unchanged by synbiotic treatment in patients with NAFLD J Bilson, CJ Oquendo, J Read, E Scorletti, PR Afolabi, J Lord, LB Bindels, ... Metabolism 151, 155759, 2024 | 7 | 2024 |
| Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: an updated meta-analysis A Mantovani, A Csermely, J Bilson, N Borella, S Enrico, B Pecoraro, ... Gut 73 (9), 1554-1561, 2024 | 4 | 2024 |
| Lipid droplets in steatotic liver disease J Bilson, E Scorletti Current Opinion in Clinical Nutrition & Metabolic Care 27 (2), 91-97, 2024 | 3 | 2024 |
| Non-alcoholic fatty liver disease (NAFLD): a multi-system disease influenced by ageing and sex, and affected by adipose tissue and intestinal function J Bilson, JK Sethi, CD Byrne Proc Nutr Soc, 1-34, 2021 | 3 | 2021 |
| Bile Acids as Emerging Players at the Intersection of Steatotic Liver Disease and Cardiovascular Diseases J Bilson, E Scorletti, JR Swann, CD Byrne Biomolecules 14 (7), 841, 2024 | 2 | 2024 |
| Fatty liver disease and risk of all cause and cause-specific mortality outcomes in the older population J Bilson, CD Byrne Hepatobiliary Surgery and Nutrition 12 (6), 949, 2023 | 2 | 2023 |
| Impact of Metabolic Syndrome Traits on Kidney Disease Risk in Individuals with MASLD: A UK Biobank Study J Bilson, TJ Hydes, D McDonnell, RM Buchanan, E Scorletti, A Mantovani, ... Liver International, 2024 | | 2024 |
| Elevated plasma hepcidin concentrations are associated with an increased risk of mortality and nonfatal cardiovascular events in patients with type 2 diabetes: a prospective study A Mantovani, F Busti, N Borella, E Scoccia, B Pecoraro, E Sani, ... Cardiovascular Diabetology 23 (1), 305, 2024 | | 2024 |
| ALTERATIONS IN THE ADIPOSE TISSUE TRANSCRIPTOMIC PROFILE ARE ASSOCIATED WITH≥ F2 LIVER FIBROSIS BUT ARE UNCHANGED BY A SYNBIOTIC INTERVENTION IN NAFLD J Bilson, CJ Oquendo, E Scorletti, J Lord, PR Afolabi, G Targher, ... The Liver Meeting 2023, 2023 | | 2023 |
| NAFLD severity and relationships with GDF-15 concentrations, PNPLA3-I148M genotype and adipose tissue biology. J Bilson University of Southampton, 2023 | | 2023 |
| Growth differentiation factor-15 as a mediating factor in the association between type 2 diabetes and liver fibrosis in NAFLD J Bilson, E Scorletti, LB Bindels, PR Afolabi, G Targher, PC Calder, ... DIABETOLOGIA 64 (SUPPL 1), 350-350, 2021 | | 2021 |
| Growth differentiation factor-15 mediates the association between type 2 diabetes and liver fibrosis in non-alcoholic fatty liver disease J Bilson, E Scorletti, LB Bindels, PR Afolabi, G Targher, PC Calder, ... DIABETIC MEDICINE 38, 2021 | | 2021 |
Giovanni TargherFull Professor of Endocrinology and Diabetes, University of VeronaPotvrđena adresa e-pošte na univr.it